Companies · Biotechnology

SentreHEART Inc

REDWOOD CITY · Biotechnology

Diligence memoA one-page analyst read on SentreHEART Inc — recommendation, valuation, rhythm, risks.
$51.0M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 19%
Sector rank · raised
Series B
Latest stage · inferred · Thu Sep 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

SentreHEART Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.25× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.
  • Within the normal band (125% of peer median) for its niche.
Dormant
  • Last raise 9.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

SentreHEART Inc is one of 4291 Biotechnology companies tracked from REDWOOD CITY. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2016-09-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2012-05-14 Raised $26M (real) Modeled valuation $1.0B (est)$26M$1.0BSeries B2012Series B · 2016-09-22 Raised $25M (real) Modeled valuation $992M (est)$25M$992MSeries B2016+$25MCumulative $51M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$26.0M · 2012
Series B extension$25.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$992.2M
Base estimate est.
$50.0M
Conservative case
$3.8B
Upside case
$138.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.0B · 2012-05-142012Series B · modeled $992.2M · 2016-09-222016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
9.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
52 mo
Avg between rounds
$11.7M/yr
Capital velocity
14.1 yr
On record since
2012
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.1× above median
This company$51.0M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.4× above median
This company$25.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 15× above median
This company$992.2M
Sector median$64.2M

Raised more than 82% of sector peers (real $). Modeled value above 89% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 101.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Liquid BioScience, Inc. · Series B Raised $40.0M · modeled $1.6B (est)Amphivena Therapeutics, Inc. · Series B Raised $65.2M · modeled $1.5B (est)Tracon Pharmaceuticals, Inc. · Series B Raised $57.7M · modeled $1.5B (est)Tetra Discovery Partners, Inc. · Series B Raised $40.5M · modeled $1.4B (est)ECM Therapeutics, Inc. · Series B Raised $35.2M · modeled $1.4B (est)Recombinetics, Inc · Series B Raised $54.7M · modeled $1.3B (est)Mersana Therapeutics Inc · Series B Raised $93.7M · modeled $1.3B (est)Atox Bio Inc. · Series B Raised $35.1M · modeled $1.3B (est)Valeritas Holdings Inc. · Series B Raised $58.2M · modeled $1.3B (est)Obsidian Therapeutics, Inc. · Series B Raised $32.4M · modeled $1.3B (est)Cellular Biomedicine Group, Inc. · Series B Raised $40.5M · modeled $1.2B (est)Altor Bioscience Corp · Series B Raised $80.1M · modeled $1.2B (est)SentreHEART Inc (this company) Raised $51.0M · modeled $992.2M (est)SentreHEART Inc
CompanyStageRaised · realValue · estvs peer med.
Liquid BioScience, Inc.Series B$40.0M$1.6B2.00×
Amphivena Therapeutics, Inc.Series B$65.2M$1.5B1.93×
Tracon Pharmaceuticals, Inc.Series B$57.7M$1.5B1.93×
Tetra Discovery Partners, Inc.Series B$40.5M$1.4B1.79×
ECM Therapeutics, Inc.Series B$35.2M$1.4B1.76×
Recombinetics, IncSeries B$54.7M$1.3B1.68×
Mersana Therapeutics IncSeries B$93.7M$1.3B1.65×
Atox Bio Inc.Series B$35.1M$1.3B1.65×
Valeritas Holdings Inc.Series B$58.2M$1.3B1.65×
Obsidian Therapeutics, Inc.Series B$32.4M$1.3B1.62×
Cellular Biomedicine Group, Inc.Series B$40.5M$1.2B1.53×
Altor Bioscience CorpSeries B$80.1M$1.2B1.52×
SentreHEART Inc this companySeries B$51.0M$992.2M1.25×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$26.0M2012-05-14$144.4M$1.0B85%
Series B$25.0M2016-09-22$138.9M$992.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$26.0M2012-05-14
    • First recorded raise — entered as Series B.
    • 4 investors on this round.
  2. Series B$25.0M2016-09-22
    • Raised again after 52 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 7 investors on this round.
Intelligence
2021 ~Q1
Modeled next raise · ~52mo cadence
$25.0M
Modeled next size est.range $25.0M$40.0M
1.0×
Last step-up
$11.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Richard Ferrari14 other2016-09
Casey Tansey13 other2012-05
Paul Buckman9 other2012-05
Russell Hirsch9 other2012-05
Steven Hochberg8 other2016-09
Chen Yu6 other2016-09
Victor Tong5 other2016-09
Peter Osborne1 other2012-05
Phil Young1 other2012-05
William Cohn1 other2012-05
Greg Fung2016-09
Pam Simons2016-09
Robert Strasser2016-09
Russell Seiber2016-09
Russell Sieber2012-05
Theodore Huber2016-09
Registry & provenance

SentreHEART Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1336396
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Miromatrix Medical Inc.BiotechnologySeries B$44.8M$623.9Mnetwork1 shared operator · same sector · same stage
Nora Therapeutics, Inc.BiotechnologySeries B$38.3M$39.7Mnetwork1 shared operator · same sector · same stage
PQ Bypass, Inc.Other Health CareSeries B$56.7M$684.5Mnetwork2 shared operators · same stage
Reshape Medical, Inc.BiotechnologySeries B$75.1M$436.6Mnetwork1 shared operator · same sector · same stage
Shoulder Innovations, Inc.Other Health CareSeries B$84.7M$106.8Mnetwork2 shared operators · same stage
Molecular Assemblies, Inc.BiotechnologySeries B$50.8M$618.8Msame sector · same stage
Aureon Biosciences, Inc.BiotechnologySeries B$51.3M$668.2Msame sector · same stage
Allocure IncBiotechnologySeries B$50.5M$1.1Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Sentire Medical Systems, Inc.BiotechnologySeed$2.5M89%
Senti Biosciences, Inc.BiotechnologySeries B$221.8M88%
SentryAg Inc.BiotechnologySeed$34.5M88%
Sentrimed, Inc.BiotechnologyPre-Seed$2.8M85%
Cardiac Insight, Inc.BiotechnologySeries A$183.8M85%
Second Heart Assist, Inc.BiotechnologySeries B$39.7M85%
Resilient Biotics, Inc.BiotechnologySeries A$50.1M84%
Biorez, Inc.BiotechnologySeries A$89.0M84%
Frequently asked
How much funding has SentreHEART Inc raised?
SentreHEART Inc has raised approximately $51.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is SentreHEART Inc's estimated valuation?
Provath's modeled valuation for SentreHEART Inc is approximately $992.2M (modeled range $50.0M–$3.8B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SentreHEART Inc at?
SentreHEART Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Sep 22.
What does SentreHEART Inc do and where is it based?
SentreHEART Inc operates in the Biotechnology sector, based in REDWOOD CITY.
Explore related

See where SentreHEART Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SentreHEART Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.